<DOC>
	<DOCNO>NCT02955771</DOCNO>
	<brief_summary>This multi-center , randomize , control , open-label , phase IIa clinical study.The study observe efficacy safety Deuteporfin photodynamic therapy addition stenting compare stenting alone patient unresectable advanced Perihilar Cholangiocarcinoma .</brief_summary>
	<brief_title>Efficacy Safety Study PDT Using Deuteporfin Unresectable Advanced Perihilar Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Klatskin Tumor</mesh_term>
	<criteria>Males female age 18 old . Diagnosed radiologically biopsy cytology confirm inoperable perihilar cholangiocarcinoma Bismuth Tumor Stage Ⅲ/Ⅳ . KPS≥70 . Total Bilirubin＜85.5 umol/L . Informed consent obtain . The first diagnosis time cholangiocarcinoma &gt; 3 month randomization . Expected survival &lt; 3 month . Patients abnormal laboratory parameter : white blood cell＜3.0×10 ( 9 ) /L；hemoglobin ＜80g/L；Neutrophil Differential Count＜1.5×10 ( 9 ) /L；blood platelets＜75×10 ( 9 ) /L；or patient diseases blood system . Creatinine clearance &gt; 1.5×upper limit normal range . Patients severe liver function damage，or aspartate transaminase ( AST ) and/or alanine transaminase ( ALT ) &gt; 5×upper limit normal range . Patients intrahepatic metastasis , distant metastasis ( include distant lymph node metastasis ) ; bile duct cancer patient part primary malignant tumor . Patients activity viral hepatitis , liver cirrhosis , liver abscess , alcoholic fatty liver , primary hepatocellular carcinoma , liver disease ; patient immunoglobulin G4 ( IgG4 ) sclerosing cholangitis , primary sclerosing cholangitis , autoimmune cholangitis , cholangitis . Malignancies cholangiocarcinoma within 5 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer . Patients receive PDT treatment prior randomization . Patients receive bile duct carcinoma resection prior randomization . Patients receive chemotherapy , brachytherapy，or radiotherapy prior randomization . Patients receive metal stent treatment prior randomization . Presence infection ( active , untreated infection and/or acute bacterial fungal infection ) infection bile duct ( cholangitis ) . Uncontrolled severe hypertension [ sit systolic blood pressure ( SBP ) &gt; 180 mmHg and/or sit diastolic blood pressure ( DBP ) &gt; 110 mmHg medication ] ; severe complication hypertension diabetes . Presence severe heart , lung central nervous system disease . Presence mental illness , mental disorder accurately describe feeling , accord doctor 's advice take medication . History alcohol abuse , drug abuse past 1 year . Presence allergic diseases，or know light skin allergy porphyria , know allergic study drug ( porphyrin drug ) similar compound , cephalosporin antibiotic , type penicillin , β lactamase inhibitor . Patients need use prohibit drug proposal first 2 week screen , trial period . Patients enrol clinical trial within 3 month prior clinical trial . Pregnant , lactate woman woman childbearing potential men sexually active willing/able use medically acceptable form contraception . The researcher n't allow participate study subject . Patients unsuitable enrollment clinical trial accord investigator decision .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>photodynamic therapy ( PDT )</keyword>
	<keyword>stenting</keyword>
	<keyword>Hilar Cholangiocarcinoma</keyword>
	<keyword>Deuteporfin</keyword>
</DOC>